After being made aware of the interruption in the supply of Pregnyl® (human chorionic gonadotrophin), we are pleased to offer the following update kindly provided by the Principal Pharmacist at the Department of Health.

Professor Jayne Franklyn, Chair of the Society for Endocrinology Clinical Committee said:

"The Department of Health is in regular contact with the manufacturer and understands that the disruption in supply is due to low availability of the active ingredient, human chorionic gonadotrophin, which has resulted in a limited supply to all markets. The company has a small batch of the 5000IU strength available, which they are managing carefully by supplying direct to pharmacies. They currently have no stock of the 1500IU strength. However, it seems that the problem with the raw material has now been resolved and they are expecting future deliveries of both strengths within the next two to three months but that they cannot be certain of this timeline."

16 April 2012